-
Citizens JMP Reiterates Market Perform Rating on Inhibrx Biosciences (INBX)
-
Inhibrx, Inc. (INBX) Misses Q2 EPS by 30c
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Inhibrx, Inc. (INBX) Tops Q1 EPS by 421c
-
Inhibrx Inc. (INBX) announces CSO change and appoints new President
-
Citizens JMP Reiterates Market Perform Rating on Inhibrx Biosciences (INBX)
-
Inhibrx Inc. (INBX) Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
-
Inhibrx Inc. (INBX) Announces Loan Agreement with Oxford Finance
-
Inhibrx, Inc. (INBX) Misses Q3 EPS by 136c
-
JMP Securities Starts Inhibrx Biosciences. (INBX) at Market Perform
-
Inhibrx Inc. (INBX) Files for 2.45M Share Offering by Selling Stockholders

